Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Effective-Component Compatibility of Bufei Yishen Formula III
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Effective-Component Compatibility of Bufei Yishen Formula III (ECC-BYF III) is a specific formulation derived from the Traditional Chinese Medicine (TCM) Bufei Yishen Formula. It is composed of five active ingredients: 20-S-ginsenoside Rh1, astragaloside IV, nobiletin, icariin, and paeonol. Preclinical studies suggest that ECC-BYF III has therapeutic potential in chronic obstructive pulmonary disease (COPD) and associated conditions like mucus hypersecretion. Its proposed mechanisms of action include inhibiting mucus hypersecretion by regulating the EGFR/MEK/ERK pathway and miR-146a-5p, modulating COPD-related pathways and hub genes (such as Il1b, Ccl2, Cxcl1, Apoe, Ccl7, Ccl12, and Ccl4), activating the Pkm2/Nrf2 signaling pathway to restore mitochondrial oxidative stress, and improving mitochondrial dysfunction by inhibiting the JNK/Sab pathway.
02
Targets
DNM1L (Dynamin-related protein 1)EGFR (Epidermal growth factor receptor)MAPK3 (Mitogen-activated protein kinase 1)IL1A (Interleukin 1 alpha)IL-4 (Interleukin 4)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MFN2 (Mitofusin-2)MUC5AC (Mucin-5AC)MUC5B (Mucin-5B)NF-κBPRKN (E3 ubiquitin-protein ligase parkin)PINK1 (PTEN-induced kinase 1)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)TNFA (Tumor necrosis factor alpha (soluble))CDKN2A (Cyclin-dependent kinase inhibitor 2A)CDKN1A (Cyclin-dependent kinase inhibitor 1A)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)PKM2 (Pyruvate kinase M2 isoform)SH3BP5 (SH3 domain-binding protein 5)JNK (Mitogen-activated protein kinase kinase kinase family)
Beyond the preview
Go deeper on Effective-Component Compatibility of Bufei Yishen Formula III.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Effective-Component Compatibility of Bufei Yishen Formula III.